Phase II Placebo-Controlled Trial of Lisinopril and Coreg CR® to Reduce Cardiotoxicity in Patients with Breast Cancer Receiving (Neo)Adjuvant Chemotherapy with Trastuzumab (Herceptin®)
RATIONALE: Lisinopril or Coreg CR®, may help reduce side effects caused by trastuzumab. It
is not yet known whether lisinopril or Coreg CR® are more effective than a placebo in
reducing side effects caused by trastuzumab.
PURPOSE: This phase II trial is studying lisinopril and Coreg CR® to see how well they work
compared with a placebo in reducing side effects in patients with HER2-positive breast
cancer receiving trastuzumab.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.